Staphylococcus aureus Activates the Aryl Hydrocarbon Receptor in Human Keratinocytes

J Innate Immun. 2022;14(6):582-592. doi: 10.1159/000524033. Epub 2022 May 2.

Abstract

Staphylococcus aureus is an important pathogen causing various infections, including - as most frequently isolated bacterium - cutaneous infections. Keratinocytes as the first barrier cells of the skin respond to S. aureus by the release of defense molecules such as cytokines and antimicrobial peptides. Although several pattern recognition receptors expressed in keratinocytes such as Toll-like and NOD-like receptors have been reported to detect the presence of S. aureus, the mechanisms underlying the interplay between S. aureus and keratinocytes are still emerging. Here, we report that S. aureus induced gene expression of CYP1A1 and CYP1B1, responsive genes of the aryl hydrocarbon receptor (AhR). AhR activation by S. aureus was further confirmed by AhR gene reporter assays. AhR activation was mediated by factor(s) <2 kDa secreted by S. aureus. Whole transcriptome analyses and real-time PCR analyses identified IL-24, IL-6, and IL-1beta as cytokines induced in an AhR-dependent manner in S. aureus-treated keratinocytes. AhR inhibition in a 3D organotypic skin equivalent confirmed the crucial role of the AhR in mediating the induction of IL-24, IL-6, and IL-1beta upon stimulation with living S. aureus. Taken together, we further highlight the important role of the AhR in cutaneous innate defense and identified the AhR as a novel receptor mediating the sensing of the important skin pathogen S. aureus in keratinocytes.

Keywords: Aryl hydrocarbon receptor; Host defense; Keratinocytes; Staphylococcus aureus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Interleukin-6
  • Receptors, Aryl Hydrocarbon* / genetics
  • Staphylococcus aureus*

Substances

  • Receptors, Aryl Hydrocarbon
  • Interleukin-6

Grants and funding

This study was supported by grants from the German Research Foundation given to J. Harder (HA 3386/5-1/-2) and in parts by funding of the medical faculty of the University of Kiel.